AngioDynamics Inc. (NASDAQ:ANGO) and STRATA Skin Sciences Inc. (NASDAQ:SSKN) have been rivals in the Medical Instruments & Supplies for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics Inc.	351.50M	2.40	4.57M	0.28	78.95
STRATA Skin Sciences Inc.	30.49M	3.23	5.59M	5.10	0.63

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies. STRATA Skin Sciences Inc. appears to has lower revenue, but higher earnings than AngioDynamics Inc. The business that Presently has a higher price-to-earnings ratio is considered the more expensive of the two businesses. AngioDynamics Inc.’s current price-to-earnings ratio is higher than that of STRATA Skin Sciences Inc., which means that it is the expensive of the two.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
AngioDynamics Inc.	1.30%	3.3%	2.5%
STRATA Skin Sciences Inc.	-18.33%	-20.6%	-13.4%

Volatility and Risk

AngioDynamics Inc. has a 0.75 beta, while its volatility is 25.00% which is less volatile than Standard & Poor’s 500. STRATA Skin Sciences Inc. has a 1.31 beta and it is 31.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of AngioDynamics Inc. are 2.9 and 1.9. Competitively, STRATA Skin Sciences Inc. has 4.5 and 4 for Current and Quick Ratio. STRATA Skin Sciences Inc.’s better ability to pay short and long-term obligations than AngioDynamics Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for AngioDynamics Inc. and STRATA Skin Sciences Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
AngioDynamics Inc.	0	1	0	2.00
STRATA Skin Sciences Inc.	0	0	0	0.00

The upside potential is 1.41% for AngioDynamics Inc. with average price target of $23.

Insider & Institutional Ownership

The shares of both AngioDynamics Inc. and STRATA Skin Sciences Inc. are owned by institutional investors at 0% and 69.3% respectively. Insiders held 0.2% of AngioDynamics Inc. shares. Competitively, 1.38% are STRATA Skin Sciences Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
AngioDynamics Inc.	-4.54%	3.65%	2.15%	-2.54%	35.59%	8.64%
STRATA Skin Sciences Inc.	-1.52%	7.67%	17.88%	26.17%	152.34%	24.23%

For the past year AngioDynamics Inc. was less bullish than STRATA Skin Sciences Inc.

Summary

AngioDynamics Inc. beats on 10 of the 14 factors STRATA Skin Sciences Inc.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

STRATA Skin Sciences, Inc., a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was founded in 1989 and is based in Horsham, Pennsylvania.